Axcelead DDP Joins Lilly TuneLab to Advance AI Drug Discovery
Fujisawa, Japan, June 18, 2026 — Axcelead Drug …
Researcher Furukawa from the Discovery Technologies Business Unit to present a poster at the 53rd Annual Meeting of the Japanese Society of Toxicology (JSOT)
Researcher Furukawa from the Discovery Technologies Business Unit …
Enhancing Clinical Predictability through Human Disease-relevant Preclinical Models in CNS and Muscle Drug Discovery
Drug discovery for central nervous system (CNS) and muscle diseases continues to face major translational challenges. Conventional models often fail to capture human disease biology, while functional readouts can be difficult to reproduce, interpret, and translate into clinically meaningful outcomes.
Improving Preclinical Decision-Making in Obesity and CKD with Translational In Vivo Phenotyping
Join this webinar to find out how we can help you identify promising novel leads! In this webinar, we will showcase our integrated HTS platform and share our successful track record. We will also highlight the latest advances powered by computational chemistry and AI/ML technologies.
BIO International Convention 2026
Boston, MA
J-Pharma’s LAT1 Inhibitor JPH034 Initiates Phase 1 Clinical Trial in the United States – Axcelead DDP Supported Multiple IND-Enabling Studies –
J-Pharma Co., Ltd. (“J-Pharma”) has announced that dosing …
Move your hits to candidates faster with Axcelead
Axcelead delivers quality with speed. We maintain an 84% client …
Irbesartan but not Roflumilast Ameliorates Renal Injury in a Col4a5 R471* Mutant Mouse Model of Alport Syndrome and CKD
The World Congress of Nephrology 2026
Inducible Exon Skipping After Disease Onset as a Therapeutic Strategy for CKD：Evaluation in a Patient-Derived Mouse Model of Alport Syndrome
The World Congress of Nephrology 2026